HAYWARD, Calif., February 26, 2025--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March:
Leerink Global Healthcare Conference 2025
Date: Wednesday, March 12th, 2025
Location: Miami Beach, FL
Format: Fireside chat & 1x1 meetings
Time: 8:00 a.m. ET
Barclays 27th Annual Global Healthcare Conference
Date: Thursday, March 13th, 2025
Location: Miami Beach, FL
Format: Fireside chat & 1x1 meetings
Time: 8:00 a.m. ET
Live webcasts of the fireside chats and panel will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, A2a/A2b receptors, CD39 and AXL. For more information about Arcus Biosciences’s clinical and preclinical programs, please visit www.arcusbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226469708/en/
Contacts
Investor Inquiries
Pia Eaves (Banerjee)
Head of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Maryam Bassiri
AD, Corporate Communications
(510) 406-8520
mbassiri@arcusbio.com
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。